XNCR - Xencor assumed with a Buy at Canaccord
- Canaccord analyst William Maughan assumed coverage of Xencor ( XNCR ) with a Buy rating and $50 price target.
- Xencor has established itself as a premier antibody design company, with multiple partnerships across biopharma, Maughan tells investors.
- With a steady source of income, more partnered programs and a validated platform, the company is well positioned to advance its own proprietary platform through the clinic and generate additional upside.
- Xencor's SA Quant Rating stands with a Buy whereas, Wall St. Analysts Rating says Strong Buy (9 Very Bullish, 4 Bullish, 1 Bearish).
- Since the start of 2022, Xencor's shares were down around 23% , and over a period of one year, shares were down around 7% .
- Shares are currently +5.68% to $32.18 today.
For further details see:
Xencor assumed with a Buy at Canaccord